NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|1092619753|ref|WP_070566871|]
View 

aminopeptidase N [Corynebacterium sp. HMSC077G01]

Protein Classification

M1 family aminopeptidase( domain architecture ID 1005449)

M1 family aminopeptidase similar to aminopeptidase N, which catalyzes the cleavage of amino acids from the N-terminus of proteins or peptides

EC:  3.4.11.2
MEROPS:  M1
PubMed:  7674922
SCOP:  3001975

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
pepN_strep_liv super family cl37109
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
5-897 0e+00

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


The actual alignment was detected with superfamily member TIGR02412:

Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 826.74  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   5 NLTRTEAADRAAMLEVSHYDISLDLTTAPVGGphsAPTFASKTTISLtAKRAGSTFIDLRDAVVKSVTIDGVDATEAARY 84
Cdd:TIGR02412   1 NLTREEARLRASLITVEHYEIALDLTGADEFF---ATRCVSTNTVRL-SEPGADTFLDLLAAQIESVTLNGILDVAPVYD 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETGINvDLTEGDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGW 164
Cdd:TIGR02412  77 GSRIPLP-GLLTGENTLRVEATRAYTNTGEGLHRFVDPVDGEVYLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 165 KVVSNSVAKTGaTTDVHGNeadTFDFSVDVPLSTYLVAVCAGPWHEVTDswtgtvaphpetpaEHQpdgelTIPLGIYCR 244
Cdd:TIGR02412 156 TVISNSRETDV-TPEPADR---RWEFPETPKLSTYLTAVAAGPYHSVQD--------------ESR-----SYPLGIYAR 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 245 QSIAEYLDADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRNDTIL 324
Cdd:TIGR02412 213 RSLAQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLHRAEATRAEKENRAGVIL 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 325 HEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDTVEQ 404
Cdd:TIGR02412 293 HEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEATEYTDAWTTFAAQGKQWAYEADQLPTTHPIVADVADLADALS 372
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 405 NFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTTTGITTLAPEFH 484
Cdd:TIGR02412 373 NFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLTPEIT 452
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 485 QEDGKYTSFAVTQEgaepgaGELRDHRIAVGIYNLRGtgadAVLERTKRVEIDVRGARTDVPDLVDTPVGDVVLVNDDDL 564
Cdd:TIGR02412 453 TDGGVVSALYPESS------GPPRPHRIAIGLYDLDR----DDLRRTTLVPLTISGERTAVPQLVGKRAPALVLLNDDDL 522
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 565 TYSMIRLDEGSLATVIDNIGAFTDSMARTLCWSATWQMVRAGQMRARDFVNLVLRGIPGEDKLSVLERVIAQAVSAV-NV 643
Cdd:TIGR02412 523 TYAKVRLDPTSFDTVLAALSKLPDPLSRAVVWASLWDSVRDGELSPDDYLSTVFAHVPSETDYAVVQQVLSQLLRAVaAQ 602
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 644 YADPQwAESTGRDLLAQGLLDYAKKETDA-DRALVFVNALATVgSSNSDVADALRAIyaGDADKAGfpaVTVDTDMQWRA 722
Cdd:TIGR02412 603 YAPIA-DRPALLAVAALACRSLRRAMESGpDFQLRWLRALALT-ATDPDSLRRLLSL--LDGKIKG---LALDPDLRWRI 675
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 723 LKALVSAGLEGEEAIAELEKTDNSALGAQAAIACRASVPTLANKARVWAEATVsgDDAPSNLVIRHLLAGFnapgsgavl 802
Cdd:TIGR02412 676 IARLAALGFIDADDIAAELERDNTASGEEHAAAARAARPDAAAKREAWQKLVT--TDALPNSKQRAIIEGF--------- 744
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 803 aqaldddsRATISAEQSAtSLSEHFFAVANSWWKQFSSETAQTLLEGFYPTWEISDEAIAAAQRLLDSDETASP-VKRII 881
Cdd:TIGR02412 745 --------WQPEQALLLA-AYAERYFANLADIWKRRGPAIAQAISRGLFPATAVNYDTLATADKWLRSQADASPgLRRTL 815
                         890
                  ....*....|....*.
gi 1092619753 882 SEQQFLVQLALRAREF 897
Cdd:TIGR02412 816 LERRDAAERALRAREA 831
 
Name Accession Description Interval E-value
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
5-897 0e+00

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 826.74  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   5 NLTRTEAADRAAMLEVSHYDISLDLTTAPVGGphsAPTFASKTTISLtAKRAGSTFIDLRDAVVKSVTIDGVDATEAARY 84
Cdd:TIGR02412   1 NLTREEARLRASLITVEHYEIALDLTGADEFF---ATRCVSTNTVRL-SEPGADTFLDLLAAQIESVTLNGILDVAPVYD 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETGINvDLTEGDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGW 164
Cdd:TIGR02412  77 GSRIPLP-GLLTGENTLRVEATRAYTNTGEGLHRFVDPVDGEVYLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 165 KVVSNSVAKTGaTTDVHGNeadTFDFSVDVPLSTYLVAVCAGPWHEVTDswtgtvaphpetpaEHQpdgelTIPLGIYCR 244
Cdd:TIGR02412 156 TVISNSRETDV-TPEPADR---RWEFPETPKLSTYLTAVAAGPYHSVQD--------------ESR-----SYPLGIYAR 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 245 QSIAEYLDADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRNDTIL 324
Cdd:TIGR02412 213 RSLAQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLHRAEATRAEKENRAGVIL 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 325 HEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDTVEQ 404
Cdd:TIGR02412 293 HEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEATEYTDAWTTFAAQGKQWAYEADQLPTTHPIVADVADLADALS 372
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 405 NFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTTTGITTLAPEFH 484
Cdd:TIGR02412 373 NFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLTPEIT 452
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 485 QEDGKYTSFAVTQEgaepgaGELRDHRIAVGIYNLRGtgadAVLERTKRVEIDVRGARTDVPDLVDTPVGDVVLVNDDDL 564
Cdd:TIGR02412 453 TDGGVVSALYPESS------GPPRPHRIAIGLYDLDR----DDLRRTTLVPLTISGERTAVPQLVGKRAPALVLLNDDDL 522
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 565 TYSMIRLDEGSLATVIDNIGAFTDSMARTLCWSATWQMVRAGQMRARDFVNLVLRGIPGEDKLSVLERVIAQAVSAV-NV 643
Cdd:TIGR02412 523 TYAKVRLDPTSFDTVLAALSKLPDPLSRAVVWASLWDSVRDGELSPDDYLSTVFAHVPSETDYAVVQQVLSQLLRAVaAQ 602
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 644 YADPQwAESTGRDLLAQGLLDYAKKETDA-DRALVFVNALATVgSSNSDVADALRAIyaGDADKAGfpaVTVDTDMQWRA 722
Cdd:TIGR02412 603 YAPIA-DRPALLAVAALACRSLRRAMESGpDFQLRWLRALALT-ATDPDSLRRLLSL--LDGKIKG---LALDPDLRWRI 675
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 723 LKALVSAGLEGEEAIAELEKTDNSALGAQAAIACRASVPTLANKARVWAEATVsgDDAPSNLVIRHLLAGFnapgsgavl 802
Cdd:TIGR02412 676 IARLAALGFIDADDIAAELERDNTASGEEHAAAARAARPDAAAKREAWQKLVT--TDALPNSKQRAIIEGF--------- 744
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 803 aqaldddsRATISAEQSAtSLSEHFFAVANSWWKQFSSETAQTLLEGFYPTWEISDEAIAAAQRLLDSDETASP-VKRII 881
Cdd:TIGR02412 745 --------WQPEQALLLA-AYAERYFANLADIWKRRGPAIAQAISRGLFPATAVNYDTLATADKWLRSQADASPgLRRTL 815
                         890
                  ....*....|....*.
gi 1092619753 882 SEQQFLVQLALRAREF 897
Cdd:TIGR02412 816 LERRDAAERALRAREA 831
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
6-473 0e+00

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 668.84  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   6 LTRTEAADRAAMLEVSHYDISLDLTTApvggphsAPTFASKTTISLTAKRAG-STFIDLRDAVVKSVTIDGVDATeaARY 84
Cdd:cd09602     1 LTREEAEQRAALISVVSYDLDLDLTEG-------AETFRGTVTIRFTLREPGaSLFLDFRGGEVKSVTLNGRPLD--PSA 71
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETGINVD--LTEGDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPK 162
Cdd:cd09602    72 FDGERITLPglLKAGENTVVVEFTAPYSSDGEGLHRFVDPADGETYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPA 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 163 GWKVVSNSVAKtgATTDVHGneADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWTGtvaphpetpaehqpdgeltIPLGIY 242
Cdd:cd09602   152 DWTVISNGPET--STEEAGG--RKRWRFAETPPLSTYLFAFVAGPYHRVEDEHDG-------------------IPLGLY 208
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 243 CRQSIAEY-LDADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRND 321
Cdd:cd09602   209 CRESLAEYeRDADEIFEVTKQGLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFREEPTRAQRLRRAN 288
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 322 TILHEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDT 401
Cdd:cd09602   289 TILHEMAHMWFGDLVTMKWWDDLWLNESFADFMAAKALAEATPFTDAWLTFLLRRKPWAYRADQLPTTHPIAQDVPDLEA 368
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 1092619753 402 VEQNFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTT 473
Cdd:cd09602   369 AGSNFDGITYAKGASVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWADAWLRT 440
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
7-666 1.40e-165

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 496.09  E-value: 1.40e-165
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   7 TRTEAADRAAMLEVSHYDISLDLTTApvggphsAPTFASKTTISLTAKRAG--STFIDLRDAVVKSVTIDGVDATeaARY 84
Cdd:COG0308     4 LTRLEAYRPPGYDVTHYDLDLDLDPA-------TTRLSGTATITFTATEAPldSLVLDLKGLEVTSVTVDGKPLD--FTR 74
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETgINVDLTE-----GDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVV 159
Cdd:COG0308    75 DGER-LTITLPKplapgETFTLEIEYSGKPSNGGEGLYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVT 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 160 APKGWKVVSNSVAKTgatTDVHGNEADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWtgtvaphpetpaehqPDGeltIPL 239
Cdd:COG0308   154 VPAGWVAVSNGNLVS---ETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF---------------ASG---VPL 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 240 GIYCRQSIAEYldADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERR 319
Cdd:COG0308   213 RVYVRPGLADK--AKEAFESTKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADETATDADYERR 290
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 320 NDTILHEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADasDI 399
Cdd:COG0308   291 ESVIAHELAHQWFGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPD--DY 368
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 400 DTVEQNFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTTTGITTL 479
Cdd:COG0308   369 PEIENFFDGIVYEKGALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTL 448
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 480 APEFHQEDGKYTSFAVTQEGAEPgagelrdHRIAVGIYNLRGTGADavlerTKRVEIdVRGARTDVpdlVDTPVGDVVLV 559
Cdd:COG0308   449 EVEYEYDADGKVTLTLRQTPPRP-------HPFHIPLEVGLLGGKL-----TARTVL-LDGEQTEL---VAKPDPVLLLR 512
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 560 NDDDLTYSMIRLDegslatvidnigaftDSMARTLCWSATWqmvRAGQmraRDFVNLVLRgiPGEDKLSVLERVIAQAVS 639
Cdd:COG0308   513 LDDELAFLLAHDS---------------DPFNRWEALQALW---RDGE---ADYLDALRA--LADTDPAVRAEALALLGS 569
                         650       660
                  ....*....|....*....|....*....
gi 1092619753 640 AVNVYADPQWAESTGRDLLA--QGLLDYA 666
Cdd:COG0308   570 DQLALARAALALAAELALLRalDDLLALA 598
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
260-470 1.41e-60

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 205.22  E-value: 1.41e-60
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 260 TKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYV-FRSKPTHYLYERRN-DTILHEMAHMWFGDLVT 337
Cdd:pfam01433   6 TVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLlYDPGNSSTSDKQRVaSVIAHELAHQWFGNLVT 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 338 MQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAA---DASDIDTVeqnFDGITYAKG 414
Cdd:pfam01433  86 MKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQnvnDPSEIDDI---FDAIPYEKG 162
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*..
gi 1092619753 415 ASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGR-DLSGWADQW 470
Cdd:pfam01433 163 ASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGPlDVDSFMDTW 219
pepN PRK14015
aminopeptidase N; Provisional
288-464 2.34e-04

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 45.12  E-value: 2.34e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 288 YNMGAMENAGCvtirdeYVFRSKpthYL-----------YERRNDTILHEMAHMWFGDLVTMQWWDDLWLNE-------- 348
Cdd:PRK14015  263 FNMGAMENKGL------NIFNSK---YVladpetatdadYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEgltvfrdq 333
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 349 --SFATWSAA-----------AAQvevsdyshawttFAnvekawaykQDQLPSTHPIAADA-SDIDtveqNFDGIT-YAK 413
Cdd:PRK14015  334 efSADLGSRAvkriedvrvlrAAQ------------FA---------EDAGPMAHPVRPDSyIEIN----NFYTATvYEK 388
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|.
gi 1092619753 414 GASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLS 464
Cdd:PRK14015  389 GAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLS 439
 
Name Accession Description Interval E-value
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
5-897 0e+00

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 826.74  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   5 NLTRTEAADRAAMLEVSHYDISLDLTTAPVGGphsAPTFASKTTISLtAKRAGSTFIDLRDAVVKSVTIDGVDATEAARY 84
Cdd:TIGR02412   1 NLTREEARLRASLITVEHYEIALDLTGADEFF---ATRCVSTNTVRL-SEPGADTFLDLLAAQIESVTLNGILDVAPVYD 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETGINvDLTEGDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGW 164
Cdd:TIGR02412  77 GSRIPLP-GLLTGENTLRVEATRAYTNTGEGLHRFVDPVDGEVYLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 165 KVVSNSVAKTGaTTDVHGNeadTFDFSVDVPLSTYLVAVCAGPWHEVTDswtgtvaphpetpaEHQpdgelTIPLGIYCR 244
Cdd:TIGR02412 156 TVISNSRETDV-TPEPADR---RWEFPETPKLSTYLTAVAAGPYHSVQD--------------ESR-----SYPLGIYAR 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 245 QSIAEYLDADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRNDTIL 324
Cdd:TIGR02412 213 RSLAQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLHRAEATRAEKENRAGVIL 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 325 HEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDTVEQ 404
Cdd:TIGR02412 293 HEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEATEYTDAWTTFAAQGKQWAYEADQLPTTHPIVADVADLADALS 372
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 405 NFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTTTGITTLAPEFH 484
Cdd:TIGR02412 373 NFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLTPEIT 452
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 485 QEDGKYTSFAVTQEgaepgaGELRDHRIAVGIYNLRGtgadAVLERTKRVEIDVRGARTDVPDLVDTPVGDVVLVNDDDL 564
Cdd:TIGR02412 453 TDGGVVSALYPESS------GPPRPHRIAIGLYDLDR----DDLRRTTLVPLTISGERTAVPQLVGKRAPALVLLNDDDL 522
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 565 TYSMIRLDEGSLATVIDNIGAFTDSMARTLCWSATWQMVRAGQMRARDFVNLVLRGIPGEDKLSVLERVIAQAVSAV-NV 643
Cdd:TIGR02412 523 TYAKVRLDPTSFDTVLAALSKLPDPLSRAVVWASLWDSVRDGELSPDDYLSTVFAHVPSETDYAVVQQVLSQLLRAVaAQ 602
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 644 YADPQwAESTGRDLLAQGLLDYAKKETDA-DRALVFVNALATVgSSNSDVADALRAIyaGDADKAGfpaVTVDTDMQWRA 722
Cdd:TIGR02412 603 YAPIA-DRPALLAVAALACRSLRRAMESGpDFQLRWLRALALT-ATDPDSLRRLLSL--LDGKIKG---LALDPDLRWRI 675
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 723 LKALVSAGLEGEEAIAELEKTDNSALGAQAAIACRASVPTLANKARVWAEATVsgDDAPSNLVIRHLLAGFnapgsgavl 802
Cdd:TIGR02412 676 IARLAALGFIDADDIAAELERDNTASGEEHAAAARAARPDAAAKREAWQKLVT--TDALPNSKQRAIIEGF--------- 744
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 803 aqaldddsRATISAEQSAtSLSEHFFAVANSWWKQFSSETAQTLLEGFYPTWEISDEAIAAAQRLLDSDETASP-VKRII 881
Cdd:TIGR02412 745 --------WQPEQALLLA-AYAERYFANLADIWKRRGPAIAQAISRGLFPATAVNYDTLATADKWLRSQADASPgLRRTL 815
                         890
                  ....*....|....*.
gi 1092619753 882 SEQQFLVQLALRAREF 897
Cdd:TIGR02412 816 LERRDAAERALRAREA 831
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
6-473 0e+00

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 668.84  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   6 LTRTEAADRAAMLEVSHYDISLDLTTApvggphsAPTFASKTTISLTAKRAG-STFIDLRDAVVKSVTIDGVDATeaARY 84
Cdd:cd09602     1 LTREEAEQRAALISVVSYDLDLDLTEG-------AETFRGTVTIRFTLREPGaSLFLDFRGGEVKSVTLNGRPLD--PSA 71
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETGINVD--LTEGDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPK 162
Cdd:cd09602    72 FDGERITLPglLKAGENTVVVEFTAPYSSDGEGLHRFVDPADGETYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPA 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 163 GWKVVSNSVAKtgATTDVHGneADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWTGtvaphpetpaehqpdgeltIPLGIY 242
Cdd:cd09602   152 DWTVISNGPET--STEEAGG--RKRWRFAETPPLSTYLFAFVAGPYHRVEDEHDG-------------------IPLGLY 208
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 243 CRQSIAEY-LDADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRND 321
Cdd:cd09602   209 CRESLAEYeRDADEIFEVTKQGLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFREEPTRAQRLRRAN 288
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 322 TILHEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDT 401
Cdd:cd09602   289 TILHEMAHMWFGDLVTMKWWDDLWLNESFADFMAAKALAEATPFTDAWLTFLLRRKPWAYRADQLPTTHPIAQDVPDLEA 368
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 1092619753 402 VEQNFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTT 473
Cdd:cd09602   369 AGSNFDGITYAKGASVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWADAWLRT 440
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
7-666 1.40e-165

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 496.09  E-value: 1.40e-165
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753   7 TRTEAADRAAMLEVSHYDISLDLTTApvggphsAPTFASKTTISLTAKRAG--STFIDLRDAVVKSVTIDGVDATeaARY 84
Cdd:COG0308     4 LTRLEAYRPPGYDVTHYDLDLDLDPA-------TTRLSGTATITFTATEAPldSLVLDLKGLEVTSVTVDGKPLD--FTR 74
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  85 ASETgINVDLTE-----GDHTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVV 159
Cdd:COG0308    75 DGER-LTITLPKplapgETFTLEIEYSGKPSNGGEGLYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVT 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 160 APKGWKVVSNSVAKTgatTDVHGNEADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWtgtvaphpetpaehqPDGeltIPL 239
Cdd:COG0308   154 VPAGWVAVSNGNLVS---ETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF---------------ASG---VPL 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 240 GIYCRQSIAEYldADTLFKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERR 319
Cdd:COG0308   213 RVYVRPGLADK--AKEAFESTKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADETATDADYERR 290
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 320 NDTILHEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADasDI 399
Cdd:COG0308   291 ESVIAHELAHQWFGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPD--DY 368
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 400 DTVEQNFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWLTTTGITTL 479
Cdd:COG0308   369 PEIENFFDGIVYEKGALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTL 448
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 480 APEFHQEDGKYTSFAVTQEGAEPgagelrdHRIAVGIYNLRGTGADavlerTKRVEIdVRGARTDVpdlVDTPVGDVVLV 559
Cdd:COG0308   449 EVEYEYDADGKVTLTLRQTPPRP-------HPFHIPLEVGLLGGKL-----TARTVL-LDGEQTEL---VAKPDPVLLLR 512
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 560 NDDDLTYSMIRLDegslatvidnigaftDSMARTLCWSATWqmvRAGQmraRDFVNLVLRgiPGEDKLSVLERVIAQAVS 639
Cdd:COG0308   513 LDDELAFLLAHDS---------------DPFNRWEALQALW---RDGE---ADYLDALRA--LADTDPAVRAEALALLGS 569
                         650       660
                  ....*....|....*....|....*....
gi 1092619753 640 AVNVYADPQWAESTGRDLLA--QGLLDYA 666
Cdd:COG0308   570 DQLALARAALALAAELALLRalDDLLALA 598
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
21-472 1.20e-98

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 315.67  E-value: 1.20e-98
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  21 SHYDISLDLTtapvggpHSAPTFASKTTISLTAKRAGSTFI----DLrdaVVKSVTIDGVDATEAARYASETGINVDLTE 96
Cdd:cd09601     1 LHYDLTLTPD-------LENFTFSGSVTITLEVLEPTDTIVlhakDL---TITSASLTLKGGSGIIEVTVVTDEETEFLT 70
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  97 GDHTVVIDADCRYT----------NNGQGIHR--FQDPADGETYLYS-QFETADAKRVFACFDQPDLKATYSIHVVAPKG 163
Cdd:cd09601    71 ITLDETLPPGENYTlsieftgklnDDLRGFYRssYTDEDGETRYLAAtQFEPTDARRAFPCFDEPAFKATFDITITHPKG 150
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 164 WKVVSNSvAKTGATTDVHGNEADTFDFSVdvPLSTYLVAVCAGPWHEVTDSwtgtvaphpetpaehqpdGELTIPLGIYC 243
Cdd:cd09601   151 YTALSNM-PPVESTELEDGWKTTTFETTP--PMSTYLVAFVVGDFEYIEST------------------TKSGVPVRVYA 209
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 244 RQSIAEYLD--ADTlfkeTKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRN- 320
Cdd:cd09601   210 RPGKIEQGDfaLEV----APKILDFYEDYFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRv 285
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 321 -DTILHEMAHMWFGDLVTMQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDI 399
Cdd:cd09601   286 aEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESP 365
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 1092619753 400 DTVEQNFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGR----DLSGWADQWLT 472
Cdd:cd09601   366 SEISEIFDAISYSKGASVLRMLENFLGEEVFRKGLRKYLKKHAYGNATTDDLWEALQEASGEskplDVKEIMDSWTL 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
22-457 2.84e-94

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 303.21  E-value: 2.84e-94
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  22 HYDISLDLTTapvggphSAPTFASKTTISLTAKRAGSTFI-DLRDAVVKSVTIDGVDATEAARYA---SETGINVDLTEG 97
Cdd:cd09595     2 HYDLDLDVDF-------TTKTLNGTETLTVDASQVGRELVlDLVGLTIHSVSVNGAAVDFGEREHydgEKLTIPGPKPPG 74
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  98 D-HTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGWKVVSNSvAKTGA 176
Cdd:cd09595    75 QtFTVRISFEAKPSKNLLGWLWEQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKDLLASNG-ALVGE 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 177 TTDvhGNEADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWTgTVAPHPetpaehqpdgeltipLGIYCRQSiaEYLDADTL 256
Cdd:cd09595   154 ETG--ANGRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVK-SQPRVG---------------LSVYSEPL--QVDQAQYA 213
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 257 FKETKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYVFRSKPTHYLYERRNDTILHEMAHMWFGDLV 336
Cdd:cd09595   214 FDATRAALAWFEDYFGGPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKVTDTGARSIENVIAHELAHQWFGNLV 293
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 337 TMQWWDDLWLNESFATWSAAAAQVEVSDYShAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDTVEQNFDGITYAKGAS 416
Cdd:cd09595   294 TMRWWNDLWLNEGFAVYYENRIMDATFGTS-SRHLDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGAL 372
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|.
gi 1092619753 417 TLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSE 457
Cdd:cd09595   373 VLRMLEELVGEEAFDKGVQAYFNRHKFKNATTDDFIDALEE 413
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
20-471 2.49e-79

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 262.91  E-value: 2.49e-79
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  20 VSHYDISLDLTTAPvggphsaPTFASKTTISLTAKRAGSTF-IDLRDAVVKSVTIDGVDATEAARYASETGINVD--LTE 96
Cdd:cd09603     3 VLHYDLDLDYDPAT-------KSLSGTATITFRATQDLDSLqLDLVGLTVSSVTVDGVPAAFFTHDGDKLVITLPrpLAA 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  97 GD-HTVVIDADCRYTNNGQGIHRFQDPADGETYLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGWKVVSNsvaktG 175
Cdd:cd09603    76 GEtFTVTVRYSGKPRPAGYPPGDGGGWEEGDDGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVVSN-----G 150
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 176 --ATTDVHGNEADTFDFSVDVPLSTYLVAVCAGPWHEVTDSWTGTvaphpetpaehqpdgeltIPLGIYCRQSIAEylDA 253
Cdd:cd09603   151 rlVSTTTNGGGTTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGG------------------IPLRYYVPPGDAA--KA 210
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 254 DTLFKETKEGFDFYAKHFGePYPFGKYDQIFCPEYNmGAMENAGCVTIRDEYVFRSKPthylYERrndTILHEMAHMWFG 333
Cdd:cd09603   211 KASFARTPEMLDFFEELFG-PYPFEKYGQVVVPDLG-GGMEHQTATTYGNNFLNGDRG----SER---LIAHELAHQWFG 281
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 334 DLVTMQWWDDLWLNESFATWSAAAaqvevsdyshaWTTFANVEKAWAYKQDQLPSTHPIAADASDI-DTVEQNFDGITYA 412
Cdd:cd09603   282 DSVTCADWADIWLNEGFATYAEWL-----------WSEHKGGADAYRAYLAGQRQDYLNADPGPGRpPDPDDLFDRDVYQ 350
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 1092619753 413 KGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWL 471
Cdd:cd09603   351 KGALVLHMLRNLLGDEAFFAALRAYLARYAHGNVTTEDFIAAAEEVSGRDLTWFFDQWL 409
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
260-470 1.41e-60

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 205.22  E-value: 1.41e-60
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 260 TKEGFDFYAKHFGEPYPFGKYDQIFCPEYNMGAMENAGCVTIRDEYV-FRSKPTHYLYERRN-DTILHEMAHMWFGDLVT 337
Cdd:pfam01433   6 TVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLlYDPGNSSTSDKQRVaSVIAHELAHQWFGNLVT 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 338 MQWWDDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAA---DASDIDTVeqnFDGITYAKG 414
Cdd:pfam01433  86 MKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQnvnDPSEIDDI---FDAIPYEKG 162
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*..
gi 1092619753 415 ASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGR-DLSGWADQW 470
Cdd:pfam01433 163 ASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGPlDVDSFMDTW 219
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
557-883 6.20e-31

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 123.92  E-value: 6.20e-31
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 557 VLVNDDDLTYSMIRLDEGSLATVIDN-IGAFTDSMARTLCWSATWQMVRAGQMRARDFVNLVLRgIPGEDKLSVLERVIA 635
Cdd:pfam11838   2 VKLNADDTGYYRVNYDPESLAALLEQlLSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLA-YLNETDYVVWSAALS 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 636 QAVSAVNVYADPQWAE---STGRDLL---AQGLLDYAKKETDADRALVFVNALATVGSSN-SDVADALRAIYAGDADKAG 708
Cdd:pfam11838  81 QLSTLRSLLSADPEYEalkAFLRKLLsplAEKLGWEAPPGESHLDRQLRALLLSAACSAGdPECVAEAKKLFDAWLDGDD 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 709 fpavTVDTDMQWRALKALVSAGLEGE-EAIAELEKTDNSALGAQAAIACRASVPTLANKARVWAEATvsGDDAPSNLVIR 787
Cdd:pfam11838 161 ----AIPPDLRWAVYCAAVANGGEAEwDALLERYRDTTSPSEKERALRALAATPDPELLQRALELAL--DSDEVRNQDLR 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 788 HLLAGFNAPGSGAVLaqaldddsratisaeqsATSLSEHFFAVANSWWKqfSSETAQTLLEGFYPTWEiSDEAIAAAQRL 867
Cdd:pfam11838 235 AVIAGLASNPAGRDL-----------------AWDFVKENWDALVKRLG--GGSSLGRLVKGLTPSFS-TEEELDEVEAF 294
                         330
                  ....*....|....*.
gi 1092619753 868 LDSDETASpVKRIISE 883
Cdd:pfam11838 295 FADKDTPG-LRRALAQ 309
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
20-471 1.26e-25

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 111.01  E-value: 1.26e-25
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  20 VSHYDISLDLTtapvggphsaptFASKT-----TISLTAKRAGSTFIDL--RDAVVKSVTIDGVDAT----EAARYASET 88
Cdd:cd09599    13 TTHLDLDLTVD------------FDKKTisgsaTLTLEVLQDGADELVLdtRDLDISSVTVNGGKELkfelGPRDPVLGS 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  89 GINVDLTEGDH-----TVVIdadcRY--TNNGQGIHrFQDP---ADGET-YLYSQFETADAKRVFACFDQPDLKATYSIH 157
Cdd:cd09599    81 ALTITLPSPLAkgdtfKVKI----EYstTPQATALQ-WLTPeqtAGKKHpYLFTQCQAIHARSLFPCQDTPSVKSTYSAT 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 158 VVAPKGWKVVSnSVAKTGATTDVHGNeadTFDFSVDVPLSTYLVAVCAGpwhEVtdswtgtvaphpetpaEHQPDGELTi 237
Cdd:cd09599   156 VTVPKGLTALM-SALRTGEKEEAGTG---TYTFEQPVPIPSYLIAIAVG---DL----------------ESREIGPRS- 211
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 238 plGIYCRQSI---AEYLDADT-LFKETKEGFdfyakhFGePYPFGKYDQIFCPE-YNMGAMENAgCVTirdeyvFRSkPT 312
Cdd:cd09599   212 --GVWAEPSVvdaAAEEFADTeKFLKAAEKL------YG-PYVWGRYDLLVLPPsFPYGGMENP-CLT------FAT-PT 274
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 313 HYLYERRN-DTILHEMAHMWFGDLVTMQWWDDLWLNESFATW----------SAAAAQVE-VSDYSHAWTTFANvekawa 380
Cdd:cd09599   275 LIAGDRSLvDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYlerrilerlyGEEYRQFEaILGWKDLQESIKE------ 348
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 381 YKQDQLPSTHPIAADASDIDTVeqnFDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFAD----LLEALS 456
Cdd:cd09599   349 FGEDPPYTLLVPDLKGVDPDDA---FSSVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTEDfkdfLLEYFA 425
                         490
                  ....*....|....*..
gi 1092619753 457 EASGRDLSG--WaDQWL 471
Cdd:cd09599   426 EDKPEILDKidW-DAWL 441
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
252-471 2.10e-24

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 107.36  E-value: 2.10e-24
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 252 DADTLFKETKEGFDFYAKHFGePYPFGKYDqIFCPEYNMGAMENAGCVTIRDEYvfrSKPTHYLYErrndTILHEMAHmw 331
Cdd:cd09604   235 AAERALEYAKDALEFFSEKFG-PYPYPELD-VVQGPFGGGGMEYPGLVFIGSRL---YDPKRSLEG----VVVHEIAH-- 303
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 332 fgdlvtmQWW---------DDLWLNESFATWSAAAAQVEVSDYSHAWTTFANVEKAWAYKQDQLPSTHPIAADASDIDTv 402
Cdd:cd09604   304 -------QWFygivgnderREPWLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYARGPGGPINLPLDTFPDGSYY- 375
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 1092619753 403 eqnfDGITYAKGASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLSGWADQWL 471
Cdd:cd09604   376 ----SNAVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSGKDLDWFFRGWL 440
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
21-509 8.13e-19

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 91.38  E-value: 8.13e-19
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  21 SHYDISLDLTTAPVGGphsaptfasKTTISLTAKRAGSTFI--DLRDAVVKSVTIDGVDA----TEAARY-ASETGINV- 92
Cdd:TIGR02411  16 TDLNLSVDFTKRKLSG---------SVTFTLKSLTDNLNKLvlDTSYLDIQKVTINGLPAdfaiGERKEPlGSPLTISLp 86
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  93 DLTEGDHTVVIDADCRYTNNGQGIhRFQDP--ADGET--YLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKgwkVVS 168
Cdd:TIGR02411  87 IATSKNDEFVLNISFSTTPKCTAL-QWLNPeqTSGKKhpYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESPL---PVL 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 169 NSVAKTGATTdvhgNEADTFDFSVDVPLSTYLVAVCAGpwhevtDSWTGTVAPHPETPAEhqpdgeltiPLGIycrQSIA 248
Cdd:TIGR02411 163 MSGIRDGETS----NDPGKYLFKQKVPIPAYLIAIASG------DLASAPIGPRSTVYSE---------PEQL---EKCQ 220
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 249 EYLDADT-LFKETKEGFDFyakhfgePYPFGKYDQ-IFCPEYNMGAMENAgCVTIrdeyvfrSKPTHYLYERRN-DTILH 325
Cdd:TIGR02411 221 YEFENDTeKFIKTAEDLIF-------PYEWGQYDLlVLPPSFPYGGMENP-NLTF-------ATPTLIAGDRSNvDVIAH 285
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 326 EMAHMWFGDLVTMQWWDDLWLNESFATWS----AAAAQVEVSDYSHA---WTTFANVEKAWaykqDQLPSTHPIAADASD 398
Cdd:TIGR02411 286 ELAHSWSGNLVTNCSWEHFWLNEGWTVYLerriIGRLYGEKTRHFSAligWGDLQESVKTL----GETPEFTKLVVDLKD 361
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 399 IDTvEQNFDGITYAKGASTLKQLAAYVG-QDAFLAGARLHFSRHRFGNATFADLLEAL-------SEASGRDLSGWaDQW 470
Cdd:TIGR02411 362 NDP-DDAFSSVPYEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKSLDTYQFKDALyeyfkdkKKVDKLDAVDW-ETW 439
                         490       500       510       520
                  ....*....|....*....|....*....|....*....|....*..
gi 1092619753 471 LTTTG--------ITTLAPEFHQEDGKYTSFAVTQEGAEPGAGELRD 509
Cdd:TIGR02411 440 LYSPGmppvkpnfDTTLADECYALADRWVDAAKADDLSSFNAKDIKD 486
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
22-200 1.10e-16

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 78.93  E-value: 1.10e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  22 HYDISLDLTTAPVggphsapTFASKTTISLTAKRAGS------TFIDLRDAVV-KSVTIDGVDATEAARYASETGINVDL 94
Cdd:pfam17900   4 HYDLDLKIDLKNF-------TFSGSVTITLQLNNATNvivlhaSDLTIRSISLsDEVTSDGVPADFTEDQKDGEKLTIVL 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753  95 TE-----GDHTVVIDADCRYTNNGQGIHRFQDPADGET--YLYSQFETADAKRVFACFDQPDLKATYSIHVVAPKGWKVV 167
Cdd:pfam17900  77 PEtlnqtGPYTLEIEYSGELNDSMTGFYRSTYTDNGEKkvLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTAL 156
                         170       180       190
                  ....*....|....*....|....*....|...
gi 1092619753 168 SNSVAKtgaTTDVHGNEADTFDFSVDVPLSTYL 200
Cdd:pfam17900 157 SNMPVI---ASEPLENGWVITTFEQTPKMSTYL 186
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
146-464 4.83e-16

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 81.41  E-value: 4.83e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 146 DQPDLKATYSIHVVAPKG-WKV-VSNsvaktgattdvhGNEADTFDFS--------VD-VPLSTYLVAVCAGPWHEVTDS 214
Cdd:cd09600   126 DRPDVMSKFTVTIEADKEkYPVlLSN------------GNLIEEGELPngrhfavwEDpFPKPSYLFALVAGDLGSVEDT 193
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 215 WTgtvaphpeTPaehqpDGElTIPLGIYCRqsiAEYLDadtlfketKEGFDFYA---------KHFGEPYPFGKYDQIFC 285
Cdd:cd09600   194 FT--------TK-----SGR-KVKLRIYVE---PGNED--------KCHHAMESlkkamkwdeERFGLEYDLDLFNIVAV 248
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 286 PEYNMGAMENAGCVTIRDEYVFRS--KPTHYLYERRNDTILHEMAHMWFGDLVTMQWWDDLWLNE--------SFATWSA 355
Cdd:cd09600   249 DDFNMGAMENKGLNIFNSKYVLADpeTATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEgltvfrdqEFSADMN 328
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 356 AAAQVEVSDYshawttfaNVEKAWAYKQDQLPSTHPIAADA-SDIDtveqNFDGIT-YAKGASTLKQLAAYVGQDAFLAG 433
Cdd:cd09600   329 SRAVKRIEDV--------RRLRSAQFPEDAGPMAHPIRPDSyIEIN----NFYTVTvYEKGAEVIRMLHTLLGEEGFRKG 396
                         330       340       350
                  ....*....|....*....|....*....|..
gi 1092619753 434 ARLHFSRHRfGNA-TFADLLEALSEASGRDLS 464
Cdd:cd09600   397 MDLYFERHD-GQAvTCEDFVAAMEDASGRDLS 427
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
288-469 1.26e-13

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 75.05  E-value: 1.26e-13
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 288 YNMGAMENAGCVTIRDEYVFRSK--PTHYLYERRNDTILHEMAHMWFGDLVTMQWWDDLWLNESF-----ATWSAAAAqv 360
Cdd:TIGR02414 250 FNMGAMENKGLNIFNSKYVLADPetATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLtvfrdQEFSADMT-- 327
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 361 evsdySHAWTTFANVE--KAWAYKQDQLPSTHPIAADASD-IDtveqNFDGIT-YAKGASTLKQLAAYVGQDAFLAGARL 436
Cdd:TIGR02414 328 -----SRAVKRIEDVRllRAHQFPEDAGPMAHPVRPESYVeIN----NFYTATvYEKGAEVIRMLHTLLGEEGFRKGMDL 398
                         170       180       190
                  ....*....|....*....|....*....|....*.
gi 1092619753 437 HFSRHRFGNATFADLLEALSEASGRDLSG---WADQ 469
Cdd:TIGR02414 399 YFSRHDGQAVTCEDFVAAMEDASGRDLNQfrrWYSQ 434
pepN PRK14015
aminopeptidase N; Provisional
288-464 2.34e-04

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 45.12  E-value: 2.34e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 288 YNMGAMENAGCvtirdeYVFRSKpthYL-----------YERRNDTILHEMAHMWFGDLVTMQWWDDLWLNE-------- 348
Cdd:PRK14015  263 FNMGAMENKGL------NIFNSK---YVladpetatdadYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEgltvfrdq 333
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 349 --SFATWSAA-----------AAQvevsdyshawttFAnvekawaykQDQLPSTHPIAADA-SDIDtveqNFDGIT-YAK 413
Cdd:PRK14015  334 efSADLGSRAvkriedvrvlrAAQ------------FA---------EDAGPMAHPVRPDSyIEIN----NFYTATvYEK 388
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|.
gi 1092619753 414 GASTLKQLAAYVGQDAFLAGARLHFSRHRFGNATFADLLEALSEASGRDLS 464
Cdd:PRK14015  389 GAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLS 439
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
257-351 2.89e-04

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 40.93  E-value: 2.89e-04
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1092619753 257 FKETKEGFDFYAKHFGE----PYPFGKYDQIFCPEYNMGAMENAGCVTIrDEYVFRSKPTHYLyERRNDTILHEMAHMWF 332
Cdd:cd09594     1 TSYAHETYKYYEELLGRtsfrYPVSPIYSLLVYPAYVEVNAYNAMWIPS-TNIFYGAGILDTL-SGTIDVLAHELTHAFT 78
                          90       100
                  ....*....|....*....|
gi 1092619753 333 GDLVT-MQWWDDLWLNESFA 351
Cdd:cd09594    79 GQFSNlMYSWSSGWLNEGIS 98
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH